Veliparib ER is under clinical development by AbbVie and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Veliparib ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Veliparib ER overview

Veliparib (ABT-888) is under development for the treatment of non- squamous non-small cell lung cancer, epithelial ovarian cancer, BRCA associated breast cancer, peritoneal cancer, fallopian tube cancer, glioblastoma multiforme, metastatic melanoma, small-cell lung cancer, testicular cancer, metastatic adenocarcinoma of the pancreas, germ cell tumors, germinomatous germ cell tumors, nongerminomatous germ cell tumors, rectal cancer, small cell lung cancer, head and neck cancer squamous cell carcinoma, oropharyngeal cancer, relapsed and refractory acute myeloid leukemia, polycythemia vera, myelofibrosis, anaplastic astrocytoma, essential thrombocythemia, chronic myelocytic leukemia, acute myelocytic leukemia, relapsed or refractory pre-B- or T-cell acute lymphoblastic leukemia (ALL), myeloproliferative disorders, diffuse large b-cell lymphoma, mantle cell lymphoma natural killer cell lymphomas and T-cell- lymphoma. It is administered oral route formulated as a capsule. It acts by targeting PARP. It is an extended release formulation.

It was also under development for solid tumor including castration resistant prostate cancer, squamous non-small cell lung cancer (NSCLC), hepatocelluar carcinoma, triple-negative breast cancer, gastric cancer, cervical cancer, metastatic melanoma, lymphoma and relapsed and/or refractory myeloma, pancreatic cancer, biliary tumor,transitional cell cancer (urothelial cell cancer),brenner tumor,endometrial cancer,clear cell squamous cell carcinoma,testicular cancer, refractory brain metastasis, HER2 positive metastatic breast cancer, esophageal cancer, HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer and prostate cancer.

AbbVie overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

For a complete picture of Veliparib ER’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.